13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001826434
Total reported value
$813.2M
$813.2M
20 檔
26.0%
According to the latest 13F quarterly dataset, Tri Locum Partners LP managed an equity portfolio of $813.2M at the end of Q3 2024, spanning 20 distinct U.S. exchange-listed positions.
Tri Locum Partners LP executed strategic sector rebalancing during Q3 2024, establishing 3 new positions while fully exiting 8 holdings and trimming 6 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PFE | Pfizer Inc | Stock-Healthcare | 12.01% | — | +190.31% | |
| 2 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 11.90% | -1.21% | +8.06% | |
| 3 | NTRA | Natera Inc | Stock-Healthcare | 9.65% | — | +37.67% | |
| 4 | STVN | Stevanato Group S.p.A. | Stock-Other | 8.95% | — | +230.36% | |
| 5 | ARGX | Argenx Se - Adr | Stock-Healthcare | 8.11% | +1.51% | -16.21% | |
| 6 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 7.66% | — | +13.62% | |
| 7 | PCVX | Vaxcyte Inc | Stock-Other | 7.44% | — | +139.91% | |
| 8 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 5.22% | — | — | |
| 9 | UTHR | United Therapeutics CORP | Stock-Healthcare | 4.72% | -2.73% | +9.63% | |
| 10 | LEGN | Legend Biotech Corp-adr | Stock-Other | 4.23% | — | +1.61% | |
| 11 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 4.09% | — | — | |
| 12 | INSM | Insmed Inc | Stock-Healthcare | 2.52% | — | -54.53% | |
| 13 | BHVN | Biohaven Ltd. | Stock-Other | 2.31% | — | — | |
| 14 | ✓ | Merus N V | Stock-Other | 2.30% | — | -42.73% | |
| 15 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 2.27% | — | +335.27% | |
| 16 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 2.20% | -3.08% | -33.76% | |
| 17 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.97% | +5.13% | -70.08% | |
| 18 | NVO | Novo-nordisk A/s-spons Adr | Stock-Healthcare | 1.92% | — | +5.40% | |
| 19 | KRRO | Korro Bio Inc | Stock-Other | 0.51% | — | -10.38% | |
| 20 | ✓ | Femasys Inc | Stock-Other | 0.01% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PFE | Pfizer Inc | +7.8% | +190.31% | Add |
| 2 | STVN | Stevanato Group S.p.A. | +6.3% | +230.36% | Add |
| 3 | PCVX | Vaxcyte Inc | +5.3% | +139.91% | Add |
| 4 | ✓ | Avadel Pharmaceuticals PLC ADR | +5.2% | NEW | New buy |
| 5 | VRNA | Verona Pharma PLC - Adr | +4.1% | NEW | New buy |
| 6 | NTRA | Natera Inc | +3.3% | +37.67% | Add |
| 7 | INSP | Inspire Medical Systems Inc | +3.2% | +13.62% | Add |
| 8 | BHVN | Biohaven Ltd. | +2.3% | NEW | New buy |
| 9 | BRD1EUR | Mind Medicine Mindmed Inc | +1.6% | +335.27% | Add |
| 10 | TEVA | Teva Pharmaceutical-sp Adr | +1.4% | +8.06% | Add |
| 11 | UTHR | United Therapeutics CORP | +0.7% | +9.63% | Add |
| 12 | LEGN | Legend Biotech Corp-adr | +0.2% | +1.61% | Add |
| 13 | ARGX | Argenx Se - Adr | — | -16.21% | Trim |
| 14 | ✓ | Femasys Inc | — | — | Unchanged |
| 15 | KRRO | Korro Bio Inc | -0.1% | -10.38% | Trim |
| 16 | NVO | Novo-nordisk A/s-spons Adr | -0.4% | +5.40% | Add |
| 17 | PRAX | Praxis Precision Medicines I | -0.8% | EXIT | Sold out |
| 18 | OCUL | Ocular Therapeutix Inc | -0.9% | EXIT | Sold out |
| 19 | XENE | Xenon Pharmaceuticals Inc | -1% | EXIT | Sold out |
| 20 | MDGL | Madrigal Pharmaceuticals Inc | -2.4% | -33.76% | Trim |
| 21 | ✓ | Merus N V | -2.7% | -42.73% | Trim |
| 22 | ALNY | Alnylam Pharmaceuticals Inc | -2.8% | EXIT | Sold out |
| 23 | INSM | Insmed Inc | -2.8% | -54.53% | Trim |
| 24 | ✓ | Avadel Pharmaceuticals PLC ADR | -4.2% | EXIT | Sold out |
| 25 | AXSM | Axsome Therapeutics Inc | -4.3% | -70.08% | Trim |
| 26 | REGN | Regeneron Pharmaceuticals | -4.7% | EXIT | Sold out |
| 27 | AMGN | Amgen Inc | -6.5% | EXIT | Sold out |
| 28 | ASND | Ascendis Pharma A/S | -7.9% | EXIT | Sold out |
According to official SEC Form 13F filings, Tri Locum Partners LP reported a total U.S. public equity portfolio value of $813.2M across 20 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including PFE, TEVA, NTRA) accounted for 26.0% of total reported equity market value during Q3 2024.
Top New Position Initiated
Avadel Pharmaceuticals PLC ADR
市值: $21.8M
Top Position Liquidated / Trimmed
ASND
前期市值: $31.1M
During Q3 2024, Tri Locum Partners LP's top holdings by market value included PFE (12.0%)、TEVA (11.9%)、NTRA (9.7%). The largest single position, PFE, represented 12.0% of total portfolio value.
In Q3 2024, Tri Locum Partners LP made 27 total portfolio adjustments, initiating 3 new buys, adding to 10 positions, trimming 6 holdings, and fully liquidating 8 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.